Biodegradable Nanoparticles of mPEG-PLGA-PLL Triblock Copolymers as Novel Non-Viral Vectors for Improving siRNA Delivery and Gene SilencingThe gene silencing efficiency of mPEG-PLGA-PLL NPs is shown to be higher than that of commercially available transfecting agent Lipofectamine, while showing no cytotoxicity. The purpose of this work was to synthesize the novel biodegradable mPEG-PLGA-PLL NPs encapsulating siRNA, and examine the physical properties of NPs and in vitro siRNA release profile from NPs.
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal CancerFindings highlight clinical application of next-generation sequencing to suggest targeted therapeutic options for patients.
Diffusion Pharmaceuticals Begins Clinical Trial for Treatment of Primary Brain CancerCompany announced clinical trial testing of its lead drug candidate trans sodium crocetinate (TSC) as a first-line treatment for newly diagnosed primary brain cancer, also known as glioblastoma or GBM.
BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III ProgramBioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III Program.
Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer ImmunotherapiesData highlights novel immunomodulatory effects of entinostat in renal and prostate cancer models.
Results From Phase I Clinical Trials Demonstrate Positive Safety Data of AVI BioPharma's RNA-Based TherapeuticsAVI BioPharma, Inc. have announced positive safety results from all six dose cohorts in the single ascending dose studies of AVI-6002 and AVI-6003, AVI's lead drug candidates being evaluated for the treatment of Ebola virus and Marburg virus, respectively.
Anacor Pharmaceuticals Announces Preliminary Results from Two Safety StudiesAN2728 studies provide positive results, ointment well tolerated on large body surfaces and sensitive skin.
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer ImmunotherapyFindings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
Molecular Insight Pharmaceuticals, Inc. Presents Human Data on Detection of Metastatic Prostate CancerThe company's molecular imaging of metastatic prostate cancer in bone and soft tissue uses their new 99mTc-radiolabeled compounds.
UA Awarded National Cancer Research GrantThe $600,000 grant will fund the Center for Targeted Cancer Therapies, created in 2002 to discover new therapies to treat pancreatic cancer.
